The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Open accessAbstract
Insulin-dependent diabetes may occur in patients with cancers who are treated with checkpoint inhibitors (CPIs). We reviewed cases occurring over a 6-year period at two academic institutions and identified 27 patients in whom this developed, or an incidence of 0.9%. The patients had a variety of solid-organ cancers, but all had received either anti–PD-1 or anti–PD-L1 antibodies. Diabetes presented with ketoacidosis in 59%, and 42% had evidence of pancreatitis in the peridiagnosis period. Forty percent had at least one positive autoantibody and 21% had two or more. There was a predominance of HLA-DR4, which was present in 76% of patients. Other immune adverse events were seen in 70%, and endocrine adverse events in 44%. We conclude that autoimmune, insulin-dependent diabetes occurs in close to 1% of patients treated with anti–PD-1 or –PD-L1 CPIs. This syndrome has similarities and differences compared with classic type 1 diabetes. The dominance of HLA-DR4 suggests an opportunity to identify those at highest risk of these complications and to discover insights into the mechanisms of this adverse event.
Verifying this paper
8 of 9 steps done · this page updates itself — you can leave and come back
- Registry recordVerified
- Full textRead the full text
- Reference list51 references found
- Reference checkChecking each cited work — 50 of 50
- StatisticsNeeds the full text
- ClaimsNeeds the full text
- Cited sourcesNeeds claims to check
- Self-checkNeeds the full text
- VerificationFindings verified
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“To date, the majority of immune checkpoint inhibitor -related cases of type 1 diabetes occur in people with high-risk HLA-DR4 (present in 76% of individuals), whereas other high-risk HLA alleles are not more common than those in the general population (67).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“This immune-related adverse event occurs in just under 1% of checkpoint inhibitor -treated individuals but most commonly occurs with agents that block the programmed cell death protein 1/programmed cell death ligand 1 pathway alone or in combination with other checkpoint inhibitors (67).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“This immune-related adverse event occurs in just under 1% of checkpoint inhibitortreated individuals but most commonly occurs with agents that block the programmed cell death protein 1/programmed cell death ligand 1 pathway alone or in combination with other checkpoint inhibitors (66).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [66]
The cited source says what the claim attributes to it.
In the citing paper
“A new and emerging issue is the development of profound insulin deficiency associated with the use of immune check-point inhibitors, which may present with hyperglycemia and diabetic ketoacidosis (DKA) (4).”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It is still unclear if steroid-sparing regimens decrease the risk of PTDM with studies showing mixed results.1591–1595”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1593]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationTivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Self-citationLymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. N. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,455
Overcoming T cell exhaustion in infection and cancer
Pauken, K. E., & Wherry, E. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.008 · Cited by 1,220
Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J., Salama, A. D., Chitnis, T., Smith, R. N., Yagita∥, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 817
Flagged first, then by citations
1 of the 51 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Alzenaidi, 2017, Autoimmune diabetes presented with diabetic ketoacidosis induced by immunotherapy in an adult with melanoma, J La State Med Soc, 169, 49
Cited by
Sorted by citations
Items 301–400 of 594
Zhang, W., Chen, J., Bi, J., Ding, N., Chen, X., Wang, Z., & Jiao, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1084441 · Cited by 11
Monitoring immunomodulation strategies in type 1 diabetes
Krishnamurthy, B., Lacorcia, M., Kay, T. W. H., Thomas, H. E., & Mannering, S. I. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1206874 · Cited by 12
Cina, M. L., Venegas, J., & Young, A. (2023) · Immunological Reviews · doi:10.1111/imr.13250 · Cited by 10
Self-citationLopes, A. R., Russo, A., Li, A. Y., McCusker, M. G., Kroopnick, J. M., Scilla, K. A., Mehra, R., & Rolfo, C. D. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-408 · Cited by 10
Endocrine dysfunction induced by immune checkpoint inhibitors.
Deligiannis, N. G., Sosa, S., Danilowicz, K., & Rizzo, L. F. L. (2021) · PubMed · Cited by 10
Atezolizumab-induced Autoimmune Diabetes in a Patient with Metastatic Breast Cancer: A Case Report
Clontz, R., Dang, D., Hieger, M. A., & Becker, B. A. (2021) · Clinical Practice and Cases in Emergency Medicine · doi:10.5811/cpcem.2021.2.51508 · Cited by 10
Yılmaz, M., & Baran, A. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211028636 · Cited by 10
Gastrointestinal adverse events of immunotherapy
Cappello, G., Molea, F., Campanella, D., Galioto, F., Russo, F., & Regge, D. (2021) · BJR|Open · doi:10.1259/bjro.20210027 · Cited by 10
Hatayama, S., Kodama, S., Kawana, Y., Otake, S., Sato, D., Horiuchi, T., Takahashi, K., Kaneko, K., Imai, J., & Katagiri, H. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13807 · Cited by 10
Seo, J. H., Lim, T., Ham, A., Kim, Y. A., & Lee, M. (2022) · Medicine · doi:10.1097/md.0000000000030456 · Cited by 10
Chan, J. S. K., Lee, S., Kong, D., Lakhani, I., Ng, K., Dee, E. C., Tang, P., Lee, Y. H. A., Satti, D. I., Wong, W. T., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5616 · Cited by 10
Pancreatic adverse events in patients treated with immune checkpoint inhibitors
Hana, C. K., Rehman, T. U., Park, K., Uribe, C. R. C., Aung, P. P., Hunis, B., Salzberg, M. P., Zikria, J., & Hussein, A. M. (2023) · JGH Open · doi:10.1002/jgh3.12875 · Cited by 10
Xiao, J., Xia, Z., Wu, Z., & Fang, M. (2025) · Journal of Chemotherapy · doi:10.1080/1120009x.2025.2561459 · Cited by 9
Schönberger, E., Švitek, L., Grubišić, B., Perić, T. C., Marušić, R., Vlašić, N. V., Kizivat, T., Canecki-Varžić, S., Marić, L. S., & Bilić-Čurčić, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311619 · Cited by 9
PD-1, BTLA and TIGIT as therapeutic targets for rheumatic disease
Kuchroo, J. R., Goldman, N., & Sharpe, A. H. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01296-9 · Cited by 10
Chen, Y., Wang, X., & Duan, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1679751 · Cited by 9
Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer
Burke, M., & Rashdan, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.720759 · Cited by 9
de Filette, J. M. K., André, S., Mey, L. D., Aspeslagh, S., Karmali, R., der Auwera, B. J. R. V., & Bravenboer, B. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01190-5 · Cited by 9
Salangsang, J., Sapkota, S., Kharel, S., Gupta, P., & Kalla, A. (2023) · Cureus · doi:10.7759/cureus.35276 · Cited by 9
Diabetes in stiff-person syndrome
Heneberg, P. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.07.005 · Cited by 9
Pan, Q., & Li, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1366335 · Cited by 9
Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
Bellastella, G., Carbone, C., Scappaticcio, L., Cirillo, P., Troiani, T., Morgillo, F., Vietri, M. T., Corte, C. M. D., Falco, V. D., Napolitano, S., et al. (2021) · Cancers · doi:10.3390/cancers13164036 · Cited by 9
Saleh, A. O., Taha, R. Y., Mohamed, S., & Bashir, M. (2021) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2021_002756 · Cited by 9
Hospitalization as an Opportunity to Optimize Glycemic Control in Oncology Patients
Hiestand, A., Flory, J., & Chitkara, R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1283-6 · Cited by 9
Review article: Ketoacidosis in the emergency department
Morton, A. (2020) · Emergency Medicine Australasia · doi:10.1111/1742-6723.13503 · Cited by 9
Bastin, M., Allouchery, M., Sassier, M., Rouby, F., Eftekhari, P., Lebrun‐Vignes, B., Andréelli, F., & Bihan, K. (2021) · Therapies · doi:10.1016/j.therap.2021.03.004 · Cited by 9
Immunoendocrinology: When (neuro)endocrinology and immunology meet
Koch, C. A., & Antonelli, A. (2018) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-018-9479-7 · Cited by 9
Adverse Events Associated With Immune Checkpoint Inhibitors
Aktürk, H. K., & Michels, A. W. (2019) · JAMA · doi:10.1001/jama.2018.22119 · Cited by 9
Singh, J., Minz, R. W., Saikia, B., Nada, R., Sharma, A., Jha, S., Anand, S., Rathi, M., & D’Cruz, S. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00908-y · Cited by 8
Han, M., Jiang, L., Zhao, B., Liu, X., Yang, C., & Chen, W. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.05.014 · Cited by 8
New Perspectives in Studying Type 1 Diabetes Susceptibility Biomarkers
Park, Y. B., Ko, K. S., & Rhee, B. D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073249 · Cited by 8
Hadfield, M. J., Merkin, R. D., Rouhani, S. J., & Reynolds, K. L. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101625 · Cited by 8
Gastrointestinal disorders as immune-related adverse events
Balducci, D., Quatraccioni, C., Benedetti, A., Marzioni, M., & Maroni, L. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00039 · Cited by 8
Zhu, J., Luo, M., Liang, D., Gao, S., Zheng, Y., He, Z., Zhao, W., Yu, X., Qiu, K., & Wu, J. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109053 · Cited by 8
Ichihara, S., Kunishige, M., Kadota, N., Okano, Y., Machida, H., Hatakeyama, N., Naruse, K., Shinohara, T., & Takeuchi, E. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14736 · Cited by 8
Hara, N., Suwanai, H., Yakou, F., Ishii, K., Iwasaki, H., Abe, H., Shikuma, J., Sakai, H., Miwa, T., & Suzuki, R. (2023) · Endocrine · doi:10.1007/s12020-023-03394-8 · Cited by 8
Clinicopathologic Characteristics of Immune Checkpoint Inhibitor-related Pancreatitis
Chen, F., Vyas, M., Gosse, M. D., Deshpande, V., & Rosenbaum, M. W. (2025) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002398 · Cited by 7
Is the NOD mouse a good model for type 1 diabetes?
Wong, F. S., Pearson, J. A., & Li, W. (2025) · Diabetologia · doi:10.1007/s00125-025-06579-0 · Cited by 8
Quandt, Z., Finnigan, S. R., Hill, V., Dib, J., Burian, J., Tessler, S., Davidson, D., Naqash, A. R., Anderson, M. S., Othus, M. K. D., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.5594 · Cited by 7
Self-citationImmune checkpoint inhibitors-induced diabetes mellitus (review)
Chen, J., Hou, X., Yang, Y., Wang, C., Zhou, J., Miao, J., Gong, F., Ge, F., & Chen, W. (2024) · Endocrine · doi:10.1007/s12020-024-03942-w · Cited by 7
Singh, V., Chu, Y., Gupta, V., & Zhao, C. W. (2020) · Cureus · doi:10.7759/cureus.8395 · Cited by 7
Hughes, M. S., Pietropaolo, M., Vasudevan, M. M., Marcelli, M., & Nguyen, H. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa150 · Cited by 7
The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy
Basak, E. A., de Joode, K., Uyl, T. J. J., van der Wal, R., Schreurs, M. W. J., van den Berg, S. A. A., Hoop, E. O., van der Leest, C. H., Chaker, L., Feelders, R. A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113839 · Cited by 7
Re-Enlightenment of Fulminant Type 1 Diabetes under the COVID-19 Pandemic
Sano, H., & Imagawa, A. (2022) · Biology · doi:10.3390/biology11111662 · Cited by 7
Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors
Fujita, Y., Kamitani, F., Yamamoto, M., Fukuoka, H., Hirota, Y., Nishiyama, N., Goda, N., Okada, Y., Inaba, Y., Nakajima, H., et al. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad002 · Cited by 7
Immune checkpoint inhibitor-induced diabetes mellitus with nivolumab
Irani, A. Z., Gibbons, H., & Teh, W. X. (2023) · BMJ Case Reports · doi:10.1136/bcr-2022-253696 · Cited by 7
Ning, P., Liu, S., & Cao, H. (2024) · Journal of Medical Case Reports · doi:10.1186/s13256-023-04248-7 · Cited by 7
For the Long Haul: Management of Long-Term Survivors after Melanoma Systemic Therapy
Silverstein, J. F., Goyal, N. G., & Tsai, K. K. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01541-6 · Cited by 6
Etiologies and Outcomes of Diabetic Ketoacidosis in Cancer Patients: A Retrospective Analysis
Gandhi, A., Jeun, R., Wang, Z., Khan, S., Best, C. J., Lavis, V. R., & Thosani, S. (2025) · Cancers · doi:10.3390/cancers17172728 · Cited by 6
Endocrine Adverse Events of Immune Checkpoint Inhibitors: A Comprehensive Review
Rajan, R., & Nandakumar, D. (2025) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_47_25 · Cited by 6
Mechanisms underlying immune-related adverse events during checkpoint immunotherapy
Zhou, X., Chen, X., Han, L., & Liu, H. (2022) · Clinical Science · doi:10.1042/cs20210042 · Cited by 6
Fadlullah, M. Z. H., Lin, C.-N., Coleman, S. S., Young, A., Naqash, A. R., Hu‐Lieskovan, S., & Tan, A. C. (2024) · The Oncologist · doi:10.1093/oncolo/oyae012 · Cited by 6
Self-citationZhang, H., Zheng, J., Ren, C., Ye, C., Wu, X. O., Lv, X., Li, Y., Zhou, J., & Zhou, J. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03570-8 · Cited by 6
Zhao, R., Su, Z., Gu, J., Zhao, H., Bian, L., Yin, J., Cai, Y., Yang, T., Gu, Y., & Xu, X. (2025) · BMC Medicine · doi:10.1186/s12916-025-04001-5 · Cited by 6
Davis, B. M., Fordjour, I., Chahin, M., & Guha, A. (2023) · BMJ Case Reports · doi:10.1136/bcr-2023-255698 · Cited by 6
Greene, A., Penner, S., Kunesh, J., Altaf, A. W., McGrade, W., & Niu, J. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552241241493 · Cited by 6
Testing Immune-Related Adverse Events in Cancer Immunotherapy
Farmer, J. R. (2019) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2019.07.012 · Cited by 6
Emergency management of immune-related toxicity
Cooksley, T., Stutman, R. E., & Klotz, A. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000635 · Cited by 6
Choi, H. S., Kim, J. T., Seo, J. Y., Linkov, F. Y., Shubnikov, E., & Lee, H. K. (2021) · Korean Journal of Pediatrics · doi:10.3345/cep.2020.01501 · Cited by 6
Pembrolizumab-induced diabetes
Banatwalla, R., Kirresh, O. Z., & Ahmed, F. W. (2021) · Endokrynologia Polska · doi:10.5603/ep.a2021.0053 · Cited by 6
Wen, Y., Xiao, H.-W., Yin, J.-H., Guo, H., Shan, M.-J., Shen, L., & Liu, L. (2022) · Medicine · doi:10.1097/md.0000000000032076 · Cited by 6
Les limites des inhibiteurs de points de contrôle immunitaire et la gestion de leur toxicité
Kostine, M., Marabelle, A., Schaeverbeke, T., & Kfoury, M. (2019) · médecine/sciences · doi:10.1051/medsci/2019191 · Cited by 6
Immunotherapy of solid tumors: how safely treat the patients
Domagala-Kulawik, J. J., Leszek, P., Owczarek, W. D., Rawa, T., Stelmachowska‐Banaś, M., & Rutkowski, P. L. (2020) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15314 · Cited by 6
Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice
Parthymos, I., Liamis, G. L., Dounousi, E. C., Pentheroudakis, G. E., Mauri, D., Zarkavelis, G., & Florentin, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102979 · Cited by 6
Gómez, P. R. D. V., Romero, M. D. C. T., Portillo, C. M., Olmedo, I. S., & Brocca, M. A. M. (2021) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2021.08.007 · Cited by 5
Phang, C. A., Kumar, S., & Rohl, P. (2022) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-22-0291 · Cited by 5
Zhukova, N. V., Орлова, Р. В., Malkova, A. M., Каледина, Е. А., Demchenkova, A., Наймушина, П. А., Назаров, В. Д., Маzing, A. V., Lapin, S. V., Belyak, N. P., et al. (2022) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2022045956 · Cited by 5
Fujiwara, M., Shimizu, M., Okano, T., Maejima, Y., & Shimomura, K. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1264056 · Cited by 5
Yabuki, S., Hirai, H., MORIYA, C. T., Kusano, Y., & Hasegawa, T. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1407192 · Cited by 5
Wang, C., Cai, Y., & Feng, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1405856 · Cited by 5
Thyroid Dysfunction from Treatments for Solid Organ Cancers
Kotwal, A., & McLeod, D. S. A. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.12.006 · Cited by 5
Park, S. J., Yang, S., Lee, S.-H., Joo, S. H., Park, T., Kim, D. H., Kim, H., Park, S., Kim, J.-T., Kwack, W. G., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15020226 · Cited by 4
Pancreas-specific immune-related adverse events in patients with lung cancer: a case series study
Liu, J., Shi, Y., Fang, J., Lu, H., Yongjie, S., Xiaoyan, L., Minjiang, C., Yan, X., & Wang, M. (2024) · Immunotherapy · doi:10.1080/1750743x.2024.2354108 · Cited by 4
Zan, Y., Wei, Y., Zhang, W., Gao, X., & Si, J. (2025) · Medicine · doi:10.1097/md.0000000000042490 · Cited by 4
Huang, N., Ortega, J., Kimbrell, K., Lee, J., Scott, L. N., Peluso, E., Wang, S., Kao, E. Y., Kim, K., Olay, J., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.188843 · Cited by 4
Self-citationGo, S.-H., Cho, Y. K., & Koh, E. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0455 · Cited by 4
Fritzsch, A., Leucht, K., Röber, N., Conrad, K., Rothe, R., Wehner, R., Schumacher, U., Esteban, E., Barthélémy, P., Schmidinger, M., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105575 · Cited by 4
Li, J., Faruque, H. A., Cortes-Sanchez, E., VanBrocklin, M. W., Hu‐Lieskovan, S., Cina, M. L., Young, A., Kopec̆ek, J., & Yang, J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114193 · Cited by 4
Self-citationGiovanella, L., Tuncel, M., Campennì, A., Ruggeri, R. M., Huellner, M. W., & Ovčariček, P. P. (2025) · Cancers · doi:10.3390/cancers17162651 · Cited by 4
Wu, L., Wentworth, J. M., Liddle, C., Fewings, N., Carlino, M. S., Brown, D. A., Clifton-Bligh, R. J., Long, G. V., Scolyer, R. A., Norris, N., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci192938 · Cited by 5
Abdullah, K. M., Sharma, G., Anjum, B., Alam, M. F., Yadav, S., Singh, Y., Sinha, R. A., Venkatesh, V., Siddiqui, J. A., & Chakravarti, B. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101458 · Cited by 4
Mol, P. V., Donders, E., Lambrechts, D., & Wauters, E. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.04.003 · Cited by 4
Wang, G., Wang, J., Dong, S., Zhang, Z., Zhang, W., & Zhao, J. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12486 · Cited by 4
DISTERHAFT, P., Kerr, C., Barnett, D., & Salloum, M. (2024) · Cancer Reports · doi:10.1002/cnr2.70058 · Cited by 4
Usui, N., Imai, Y., Sugawara, K., Uchida, Y., Nakayama, N., Tomiya, T., Mizuno, S., & Mochida, S. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4688-24 · Cited by 4
Autoimmune Polyglandular Syndromes
Sperling, M. A., Angelousi, A. G., & Yau, M. (2021) · MDText.com, Inc. eBooks · Cited by 4
Circulating biomarkers of response to immunotherapy and immune-related adverse events
Garrison, Z. R., Hornick, N. I., Cheng, J. B., & Kulkarni, R. P. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2130688 · Cited by 4
Ikeda, M., Tamada, T., Takebayashi, R., Okuno, G., Yagura, I., Nakamori, S., Matsumura, T., Yoshioka, T., Kaneko, S., & Kanda, N. (2022) · Internal Medicine · doi:10.2169/internalmedicine.0860-22 · Cited by 4
Angelousi, A. G., Ziogas, D. C., Siampanopoulou, V., Mytareli, C., Anastasopoulou, A. N., Lyrarakis, G., & Gogas, H. J. (2024) · Diseases · doi:10.3390/diseases12020040 · Cited by 4
Wu, M. J., Liu, J., Seery, S., Meng, X., & Yue, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.646085 · Cited by 4
Case 6-2022: A 68-Year-Old Man with Fatigue, Weight Loss, and Hyperglycemia
Wing, J. R., Kimball, A., & Rengarajan, M. (2022) · New England Journal of Medicine · doi:10.1056/nejmcpc2115848 · Cited by 4
Bao, S., & Jiang, X. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11617 · Cited by 4
Watanabe, M., Eguchi, J., Takamoto, A., Kanzaki, H., Noda, Y., Kagawa, S., & Wada, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1439705 · Cited by 4
Sanji, E. W., Agbor, D. B. A., Orians, M., & Portnoy, D. C. (2025) · Cureus · doi:10.7759/cureus.80083 · Cited by 3
Metabolic dysregulation: Its role in diabetes mellitus and cancers
Dai, S., Li, J., Xia, J., Liu, Y., & Li, Y. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101461 · Cited by 3
Sheng, P., Guo, Y., Wu, Y., Xie, J., Wang, X., Wu, M., & An, X. (2026) · Medicine · doi:10.1097/md.0000000000048449 · Cited by 3
The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact
Hajjar, J., Stephen, B., Aaroe, A., Aiche, M. M., Al-Zubidi, N. S., Ameri, M., Brooks, K. A., Carabenciov, I. D., Chambers, M. S., Chaudhry, A. L., et al. (2026) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-26-12 · Cited by 3
Self-citationShalitin, S. (2024) · Hormone Research in Paediatrics · doi:10.1159/000537969 · Cited by 4
Onco-Primary Care of Patients Receiving Immune Checkpoint Inhibitors
Hoimes, C. J., McGettigan, S., & Schwartzberg, L. S. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.08.025 · Cited by 3
Ose, D. J., Adediran, E., Mark, B., Ocier, K., Dunson, W. A., Jr., Turner, C., Taylor, B., Svoboda, K., Post, A. R., Leiser, J. S., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70246 · Cited by 3
Metadata
- Authors
- Stamatouli, A. M., Quandt, Z., Perdigoto, A. L., Clark, P. L., Kluger, H., Weiss, S. A., Gettinger, S., Sznol, M., Young, A., Rushakoff, R., Lee, J., Bluestone, J. A., Anderson, M., & Herold, K. C.
- Affiliations
- Yale University (US)
- University of California, San Francisco (US)
- Corresponding author
- Herold, Kevan C.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2018-06-24
- Volume
- 67
- Issue
- 8
- Pages
- 1471-1480
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC6054443
- OpenAlex
- W2808896902
- Cited by
- 590
- References
- 51
- Citations by year
- 2026: 41 · 2025: 75 · 2024: 76 · 2023: 90 · 2022: 80 · 2021: 92 · 2020: 69 · 2019: 52 · 2018: 14
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK057846, UC4 DK116290)
- Leona M. and Harry B. Helmsley Charitable Trust (2018PG-T1D059)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- immune checkpoint inhibitors, type 1 diabetes, anti-PD-1, PD-L1 inhibitors, immune-related adverse events, ketoacidosis, pancreatitis, autoantibodies, HLA-DR4, solid organ cancer, endocrine adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Insulin Secretion, Animals, Autoimmune Diseases, Diabetes Mellitus, Type 1, Genotype, Humans, Hypoglycemic Agents, Insulin, Isoantibodies, Ketosis, Neoplasms, Pancreas, Pancreatitis, HLA-DR4 Antigen, Models, Immunological, Genetic Predisposition to Disease, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
